carnitine has been researched along with Thymus Neoplasms in 1 studies
Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.
Excerpt | Relevance | Reference |
---|---|---|
"The mechanism(s) of immune checkpoint inhibitor (ICI)-induced myasthenia gravis (MG), an immune-related adverse event (irAE) that is fatal and limits subsequent ICI use, remain unexplored." | 1.72 | Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. ( Chen, L; Gao, W; Gong, Q; Guo, R; Jin, S; Li, J; Liu, X; Shao, YW; Shen, L; Sun, C; Wang, Q; Wang, W; Wang, Z; Wu, L; Xu, J; Yin, JC; Zhang, W, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Gao, W | 3 |
Wu, L | 3 |
Jin, S | 3 |
Li, J | 3 |
Liu, X | 3 |
Xu, J | 3 |
Zhang, W | 3 |
Gong, Q | 3 |
Sun, C | 3 |
Wang, W | 3 |
Wang, Z | 3 |
Shao, YW | 3 |
Yin, JC | 3 |
Shen, L | 3 |
Chen, L | 3 |
Wang, Q | 3 |
Guo, R | 3 |
1 other study available for carnitine and Thymus Neoplasms
Article | Year |
---|---|
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member | 2022 |
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member | 2022 |
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member | 2022 |
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
Topics: Carnitine; Humans; Immune Checkpoint Inhibitors; Myasthenia Gravis; Solute Carrier Family 22 Member | 2022 |